Eradication of H. Pylori With the Regimen Individualized Susceptibility of H. Pylori to Clarithromycin Determined by the Mutation of 23S rRNA of H. Pylori
Phase 2
Not yet recruiting
- Conditions
- patients infected with H. pylori
- Registration Number
- JPRN-UMIN000022766
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
nder progression
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
Patients allergic to the any of the drugs used for eradication of H. pylori. Patients who do not agree to the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication rates of H. pylori is assessed bythe 13C-urea breath test performed at 1 month after the therapy.
- Secondary Outcome Measures
Name Time Method interview on the adverse events during the treatment, such as diarrhea, loose stool, abdominal pain and allergic reactions.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link 23S rRNA mutations to clarithromycin resistance in H. pylori?
How does individualized clarithromycin-based therapy compare to standard triple/quadruple regimens for H. pylori eradication?
Which H. pylori biomarkers predict successful eradication with mutation-targeted antibiotic regimens?
What adverse events are associated with clarithromycin-susceptibility guided H. pylori treatment protocols?
Are there alternative antibiotic combinations for H. pylori eradication in clarithromycin-resistant strains?